The Federal Trade Commission has issued a fresh round of warning letters to 25 companies that market or generate sales leads for healthcare plans. The notices, sent last week, follow an earlier set of letters to 24 health‑services firms in early October, both aimed at promoting price transparency and curbing deceptive marketing.
The latest batch targets firms that promote Affordable Care Act Marketplace plans. The FTC did not disclose the specific companies’ names.
“Making healthcare more transparent and affordable is a top priority for the FTC,” said Christopher Mufarrige, director of the FTC’s Bureau of Consumer Protection, in a statement. “Americans facing rising health‑care costs should not also have to worry whether a plan is what it claims to be. These letters remind companies that open enrollment is not an invitation to misrepresent coverage.”
The FTC identified several practices that may violate the FTC Act, which bars deceptive or unfair acts in commerce, including:
- misrepresenting the benefits of a health‑related product;
- falsely labeling a plan as major or comprehensive medical insurance when it is not;
- inaccurately stating the costs of a plan;
- incorrectly promising free offers or other incentives upon enrollment.
“Based on FTC staff investigations and past enforcement actions, we have observed a pattern of deceptive claims by marketers and lead generators of health insurance and related products,” the agency said in the letters. “These claims have prompted consumer complaints.”
The FTC cited prior cases such as Top Healthcare Options Insurance Agency, accused of presenting limited‑benefit and discount plans as comprehensive coverage, and Innovative Partners, alleged to have impersonated government and insurance carriers to mislead customers.
The letters are advisory rather than allegations of illegal conduct. They encourage recipients to review all marketing and advertising—including online ads, website and social‑media statements, and promotional materials—to ensure compliance with federal law. The FTC emphasized that the notices are not exhaustive and that companies remain responsible for adhering to all applicable regulations.
“FTC staff will continue to monitor this market for potentially deceptive or unfair practices and will take enforcement action where warranted,” the agency added.
Photo: boonchai wedmakawand, Getty Images
Also Read
- Servier’s $1.55 B Muscular Dystrophy Drug Fails Trials After Early Promise
- Traumatic Brain Injury Unlocks Musical Prodigy; Long COVID Treatment Advances; Delirium’s Link to Dementia Risk
- Midterm Elections and the Future of Healthcare
- First Psychedelic Approval Race: Compass Pathways Faces Closing Challenge From Non-Profit Sector

